# Rocket One Inc.: overview RKTO · Nasdaq · CIK 1711786 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/rkto.md) · [Financials](/companies/rkto/financials.md) · [Filings](/companies/rkto/filings.md) · [Insiders](/companies/rkto/insiders.md) Latest reported revenue: [$0](/filings/0001213900-24-096778.md) for Q3 FY2024, three months to 2024-09-30, from the 10-Q filed Nov 12, 2024 (XBRL us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax, accession 0001213900-24-096778). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $ | [0.0 d](/filings/0001213900-24-096778.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.32)](/filings/0001213900-25-109220.md) | not reported | [(0.27)](/filings/0001213900-26-057726.md) | [(0.17)](/filings/0001213900-26-090048.md) | [(0.30)](/filings/0001213900-25-109220.md) | not reported | [(0.17)](/filings/0001213900-26-057726.md) | [(0.19)](/filings/0001213900-26-090048.md) | | Free cash flow | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 9-month figure less the 6-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 9-month figure less the 6-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $ | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(16.02)](/filings/0001213900-23-025455.md) | [(9.50)](/filings/0001213900-24-027213.md) | [(2.38)](/filings/0001013762-25-004108.md) | [(1.28)](/filings/0001213900-26-035625.md) | [(0.90)](/filings/0001213900-26-035625.md) | | Free cash flow | $ | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/rkto/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $683.3k | 683,291 | | Added +553,600 | | [JANE STREET GROUP, LLC](/funds/1595888.md) | 2026-06-30 | $219.3k | 219,316 | | New +219,316 | | [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $211.3k | 211,304 | | Added +53,327 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $196.0k | 195,982 | | Reduced −18,262 | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $84.3k | 84,318 | | Unchanged | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $63.9k | 63,939 | | Unchanged | | [LPL Financial LLC](/funds/1403438.md) | 2026-06-30 | $41.0k | 41,029 | | New +41,029 | | [NORTHERN TRUST CORP](/funds/73124.md) | 2026-06-30 | $38.7k | 38,724 | | Reduced −3,330 | | [SUSQUEHANNA INTERNATIONAL GROUP, LLP](/funds/1446194.md) | 2026-06-30 | $26.0k | 25,966 | | New +25,966 | | [Lido Advisors, LLC](/funds/1650150.md) | 2026-06-30 | $19.5k | 19,500 | | Reduced −19,500 | ## Recent filings [All 348 filings](/companies/rkto/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-23 | 16:05 ET | [DEF 14A](/filings/0001213900-26-112099.md) | Proxy statement, period 2026-12-17 | 0001213900-26-112099 | | 2026-09-25 | 16:30 ET | [8-K](/filings/0001213900-26-103530.md) | 5.08 Item not in the standard list; 8.01 Other events | 0001213900-26-103530 | | 2026-09-22 | 16:33 ET | [8-K](/filings/0001213900-26-102217.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-26-102217 | | 2026-08-14 | 16:07 ET | [10-Q](/filings/0001213900-26-090048.md) | Quarterly report, period 2026-06-30 | 0001213900-26-090048 | | 2026-08-11 | 16:05 ET | [8-K](/filings/0001213900-26-087771.md) | 3.01 Delisting notice; 8.01 Other events | 0001213900-26-087771 | | 2026-07-31 | 16:06 ET | [8-K](/filings/0001213900-26-083962.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-26-083962 | | 2026-07-21 | 08:20 ET | [8-K](/filings/0001213900-26-079817.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-26-079817 | | 2026-06-25 | 17:12 ET | [8-K](/filings/0001213900-26-072137.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-26-072137 | | 2026-06-03 | 08:27 ET | [8-K](/filings/0001213900-26-064460.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-26-064460 | | 2026-06-03 | 08:26 ET | [8-K](/filings/0001213900-26-064457.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-26-064457 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001213900-26-035625.md), filed Mar 27, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1711786 - Tickers: RKTO - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: NV - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:46 ET. No prices; not investment advice.